On January 20, 2026, Think Bioscience (Think Bio), a Boulder-based biotechnology company focused on unlocking elusive drug targets, has raised $55 million in an oversubscribed Series A. The round was led by Regeneron Ventures, Innovation Endeavors, and Janus Henderson Investors with participation from T.A. Springer, CE-Ventures, MBX Capital, and YK Bioventures. Returning investors include AV8 Ventures, CU Innovations, and Buff Gold Ventures. Wilson Sonsini Goodrich & Rosati advised Think Bio on patent matters related to the transaction.

The Wilson Sonsini team that advised Think Bio on patent matters related to the transaction includes Sara Patak, Dalton Case, and Tess Oram.

For more information, please see Think Bio’s news release. Additional coverage can be found on Pulse 2.0 and Endpoints News.